USA Volleyball CEO Jamie Davis
COLORADO SPRINGS, Colo. (Nov. 12, 2019) – USA Volleyball’s Board of Directors has extended CEO Jamie Davis’ contract through 2024, a positive vote of confidence following major accomplishments during his first three years with the national governing body.
“Since taking over as CEO in January 2017, Jamie’s leadership has reached every realm of USA Volleyball’s operations delivering solid membership growth, financial stability, enhanced partnerships with internal and external constituents and successes on the courts”, said USA Volleyball Board Chair Dr. Cecile Reynaud. “He has been tireless in his pursuit of excellence and the Board of Directors believes he is the leader to continue our growth through the Paris Olympic and Paralympic Games.”
Under Davis’ guidance, USA Volleyball’s membership has reached a record 424,000 members. Furthermore, USA Volleyball is in a strong financial position delivering an operating surplus of over $7 million since 2017. Those funds are being reinvested into growing the sport at all levels. Such reinvestment includes the organization’s recent commitment to increasing diversity and inclusion in volleyball as exhibited by USAV’s historic grant of $400,000 to the Southern Intercollegiate Athletic Conference and six HBCU’s who will begin men’s volleyball varsity programs in 2021. USA Volleyball has deepened its relations with the FIVB and NORCECA and as a result has hosted for the first time new major international competitions in the United States over the past several years. Finally, Davis and the USAV Board have made athletes and their safety the number-one strategic priority for USA Volleyball.
“I am excited by what we have achieved as an organization over the past three years and heading into Tokyo,” Davis said. “I appreciate the confidence that the Board has placed in me and look forward to working with them, the USAV staff, our regions, NORCECA, the FIVB and our athletes to bring volleyball to even greater heights in the United States over the next quadrennial.”